Tuesday, February 7, 2023
Google search engine
HomeMarketResultsGracell Biotechnologies Inc. (NASDAQ:GRCL) Sees Large Growth in Short Interest

Gracell Biotechnologies Inc. (NASDAQ:GRCL) Sees Large Growth in Short Interest


Gracell Biotechnologies Inc. (NASDAQ:GRCLGet Rating) noticed a big progress in brief curiosity in December. As of December fifteenth, there was quick curiosity totalling 230,200 shares, a progress of 49.0% from the November thirtieth complete of 154,500 shares. Based mostly on a median buying and selling quantity of 92,500 shares, the short-interest ratio is presently 2.5 days. At present, 0.4% of the corporate’s inventory are bought quick.

Analyst Upgrades and Downgrades

A number of equities analysts have just lately weighed in on the corporate. HC Wainwright assumed protection on Gracell Biotechnologies in a report on Thursday, December eighth. They issued a “purchase” ranking and a $6.00 worth goal for the corporate. Citigroup assumed protection on Gracell Biotechnologies in a report on Thursday, September twenty second. They issued a “purchase” ranking and a $12.00 worth goal for the corporate. 5 funding analysts have rated the inventory with a purchase ranking, In accordance with knowledge from MarketBeat, the corporate presently has a consensus ranking of “Purchase” and a consensus goal worth of $13.20.

Hedge Funds Weigh In On Gracell Biotechnologies

A variety of hedge funds and different institutional buyers have just lately purchased and bought shares of GRCL. Tower Analysis Capital LLC TRC grew its holdings in Gracell Biotechnologies by 1,279.0% in the course of the third quarter. Tower Analysis Capital LLC TRC now owns 8,357 shares of the corporate’s inventory value $27,000 after buying a further 7,751 shares in the course of the interval. Jane Road Group LLC purchased a brand new stake in shares of Gracell Biotechnologies in the course of the first quarter value roughly $31,000. Vident Funding Advisory LLC boosted its holdings in shares of Gracell Biotechnologies by 58.0% in the course of the first quarter. Vident Funding Advisory LLC now owns 19,961 shares of the corporate’s inventory value $47,000 after buying a further 7,331 shares in the course of the interval. Renaissance Applied sciences LLC purchased a brand new stake in shares of Gracell Biotechnologies in the course of the first quarter value roughly $55,000. Lastly, Balyasny Asset Administration LLC purchased a brand new stake in shares of Gracell Biotechnologies in the course of the third quarter value roughly $79,000. Institutional buyers personal 45.10% of the corporate’s inventory.

Gracell Biotechnologies Inventory Efficiency

Gracell Biotechnologies stock opened at $2.30 on Friday. Gracell Biotechnologies has a 52 week low of $1.68 and a 52 week excessive of $6.52. The corporate has a present ratio of 6.77, a fast ratio of 6.77 and a debt-to-equity ratio of 0.03. The inventory has a 50-day easy shifting common of $3.02 and a 200 day easy shifting common of $3.30.

Gracell Biotechnologies (NASDAQ:GRCLGet Rating) final posted its quarterly earnings outcomes on Monday, November 14th. The corporate reported ($0.36) EPS for the quarter, lacking analysts’ consensus estimates of ($0.09) by ($0.27). As a bunch, sell-side analysts forecast that Gracell Biotechnologies will put up -0.29 earnings per share for the present fiscal 12 months.

Gracell Biotechnologies Firm Profile

(Get Rating)

Gracell Biotechnologies Inc, a clinical-stage biopharmaceutical firm, primarily discovers and develops cell therapies for the therapy of most cancers within the Folks’s Republic of China. Its lead product candidates embrace GC012F, a FasTCAR-enabled twin BCMA- and CD19-directed autologous CAR-T product candidate that’s in Section I trial for the therapy of a number of myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Section I scientific trial for the therapy of grownup B cell acute lymphoblastic leukemia (B-ALL), in addition to in preclinical stage for the therapy of relapsed or refractory (r/r) B cell non-Hodgkin’s lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Section I scientific trial for the therapy of grownup T cell acute lymphoblastic leukemia.

Learn Extra

This on the spot information alert was generated by narrative science know-how and monetary knowledge from MarketBeat so as to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Gracell Biotechnologies, you will wish to hear this.

MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers each day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Gracell Biotechnologies wasn’t on the record.

Whereas Gracell Biotechnologies at present has a “Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The Five Stocks Here

Elon Musk’s Next Move

Questioning while you’ll lastly be capable of spend money on SpaceX, StarLink or The Boring Firm? Click on the hyperlink under to study when Elon Musk will let these corporations lastly IPO.

Get This Free Report

Elon Musk's Next Move Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments